# Alexandra Lindsay

> Alexandra Lindsay is a funding round investor at Calculus Capital backing Biotechnology and Energy. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Calculus Capital](https://shizune.co/investors/profile/calculus-capital)
- Total investments: 4
- Last investment: Apr 2022
- Lead investor: 100%
- Last updated: Aug 2026

Alexandra Lindsay is a funding round investor at Calculus Capital focused on Biotechnology and Energy. Alexandra Lindsay - Investment Director @ Calculus Capital

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 50% |
| Energy | 1 | 25% |
| Medical | 1 | 25% |
| Computer | 1 | 25% |
| Genetics | 1 | 25% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 3 | 75% |
| Venture - Series Unknown | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 2 | 50% |
| United States | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Axol Bioscience | Axol specialize in human cell culture. Axol Bioscience sells live human cell cultures and provides services such as genome editing to researchers. These are iPSC-derived cells and the media and reagents required to successfully culture these cells. The company also do iPSC reprogramming and differentiation to various cell types as a service forcustomers that wish to use their own patient-derived samples.Axol is headquartered and maintains production on the Chesterford Research Park, a location renowned for inspiring innovation and success, located in Cambridge, UK. | $4.2M | Venture - Series Unknown | Apr 07, 2022 |  |
| Oxford BioTherapeutics | Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines in the field of cancer. The company has signed strategic partnerships with the leading antibody companies Medarex, Biosite and Amgen to build a broad pipeline of novel antibody therapeutics using its unique OGAP® (Oxford Genome Anatomy Project) platform. OGAP® is oneof the world’s largest proprietary human protein databases which contains and combines proteomic and genomic data with related clinical information. OBT also intends to develop companion diagnostics for selected antibody programmes. The company expects to improve disease management and treatment outcomes by integrating diagnostics into product development and commercialisation activities. | $2.6M |  | Aug 03, 2018 |  |
| Open Energy Market | Open Energy Market employs technology and expertise to create a commercial marketplace with a focus on energy buying and management. It helps energy buyers navigate a rapidly evolving industry, giving them greater control, insight, and power to build and shape lasting energy strategies.The company was founded in 2012 and is headquartered inGuildford, Surrey. | $3.9M |  | Feb 07, 2018 |  |
| Axol Bioscience | Axol specialize in human cell culture. Axol Bioscience sells live human cell cultures and provides services such as genome editing to researchers. These are iPSC-derived cells and the media and reagents required to successfully culture these cells. The company also do iPSC reprogramming and differentiation to various cell types as a service forcustomers that wish to use their own patient-derived samples.Axol is headquartered and maintains production on the Chesterford Research Park, a location renowned for inspiring innovation and success, located in Cambridge, UK. | $3.3M |  | Aug 16, 2017 |  |

4 of 4 investments shown.

## Co-investors
- [Meltwind Advisory](https://shizune.co/investors/profile/meltwind-advisory) — VC Fund, 1 deal together
- [Par Equity](https://shizune.co/investors/profile/par-equity) — VC Fund, 1 deal together
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund, 1 deal together

## About Calculus Capital

VC Fund · London, United Kingdom

At Calculus Capital they are specialists in creating and managing tax efficient private equity funds for the individual. Funds that are ideal for today's market - offering generous tax benefits, and significant growth potential within a sensible risk profile.They look to make £2-5 million investments in established companies with provenmanagement teams and a successful product or service. Their entrepreneurial flair, combined with their experience and sound commercial judgement has resulted in a diversified investment portfolio and an impressive track record. In June 2013 Calculus Capital was top ranked in the prestigious Martin Churchill Tax Efficient Review for the 6th year in a row. The Government has recently shown its support for EIS funds, by maintaining the five generous tax benefits and widening the scope of EIS investments. These changes benefit Calculus Capital's rigorous and proven strategy. As a result they are experiencing their strongest pipeline of prospective investments yet.

5 contacts available at Calculus Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Alexandra Lindsay | Investment Director | https://shizune.co/investors/profile/alexandra-lindsay |
| John Glencross | Chief Executive Officer & Co-founder | https://shizune.co/investors/profile/john-glencross |
| Richard Moore | Investment Director | https://shizune.co/investors/profile/richard-moore-37e8 |
| Robert Davis | Deputy CEO and Head of Portfolio Management | https://shizune.co/investors/profile/robert-davis-2 |
| Susan McDonald | Chairman and Co-Founder | https://shizune.co/investors/profile/susan-mcdonald-1824 |

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Alexandra Lindsay invest in?

Alexandra Lindsay invests primarily in Biotechnology, Energy and Medical startups, most often at Funding Round and Venture - Series Unknown stage. Most of the 4 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Alexandra Lindsay last invest?

The most recent investment recorded for Alexandra Lindsay closed in Apr 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co